Cartesian Therapeutics (RNAC) EBITDA Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly EBITDA Margin of 33973.08% for Q1 2026, down 3198317.0% year-over-year from N/an in Q1 2025, and down 309.12% quarter-over-quarter from 8304.01% in Q4 2025.
Cartesian Therapeutics (RNAC) EBITDA Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported EBITDA Margin for 12 consecutive years, with 33973.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 3198317.0% year-over-year to 33973.08%; the TTM figure through Mar 2026 stood at 14440.49% (down 1428412.0% YoY), while the FY2025 annual figure was 5127.1%, down 501241.0% from the prior year.
- EBITDA Margin slipped to 33973.08% in Q1 2026 per RNAC's latest filing, from 8304.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3197.49% in Q4 2024 and bottomed at 33973.08% in Q1 2026.
- Historically, EBITDA Margin has averaged 3039.4% across 5 years, with a median of 214.0% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 363702 bps — and 2026, when it sank 3198317 bps.
- Cartesian Therapeutics' EBITDA Margin stood at 50.59% in 2022, then slumped by 769 bps to 439.54% in 2023, then jumped by 827 bps to 3197.49% in 2024, then sank by 360 bps to 8304.01% in 2025, then sank by 309 bps to 33973.08% in 2026.
- Business Quant data shows RNAC's EBITDA Margin at 33973.08% in Q1 2026, 8304.01% in Q4 2025, and 1989.91% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,973.08% |
| Dec 31, 2025 | -8,304.01% |
| Mar 31, 2025 | -1,989.91% |
| Dec 31, 2024 | 3,197.49% |
| Jun 30, 2024 | 41.35% |
| Mar 31, 2024 | -228.56% |
| Dec 31, 2023 | -439.54% |
| Sep 30, 2023 | -199.44% |
| Jun 30, 2023 | -355.08% |
| Mar 31, 2023 | -309.55% |
| Dec 31, 2022 | -50.59% |
| Sep 30, 2022 | -7.72% |
| Jun 30, 2022 | 35.29% |
| Mar 31, 2022 | 31.69% |
| Dec 31, 2021 | 13.62% |
| Sep 30, 2021 | -8.06% |
| Jun 30, 2021 | 2.30% |
| Mar 31, 2021 | -64.78% |
| Dec 31, 2020 | -66.09% |
| Sep 30, 2020 | -295.61% |